Press release content from Globe Newswire. The AP news staff was not involved in its creation. Evaxion Biotech Announces Q4 and Full-Year 2020 Financial Results and Provides Business Update Evaxion BiotechApril 6, 2021 GMT Successfully completed initial public offering on U.S. Nasdaq in February 2021, raising gross proceeds of $30 million Clinical development on track with dosing of first patient in Phase 1/2a melanoma trial of cancer vaccine EVX-02 Cash reserves of $5.8 million at December 31, 2020 plus funds from IPO provide funding for at least 12 months from the date of completion of the...